The European Patent Office grants patent for RCD405

The European Patent Office (EPO) has announced that it intends to grant Respiratorius the patent application for the RESP9000 series, which includes the drug candidate RCD405, (European Patent Application No. 19740090.6 NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After the formal fees have been paid, the patent will be granted, which gives Respiratorius market exclusivity in Europe until 2039. This is the first approval for the patent family.

The RESP9000 series includes substances with the potential to be developed into drugs for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma. Preclinical research has shown that the substances have a clear bronchodilator and anti-inflammatory effect.

The development work with RCD405 is proceeding according to plan and with good results. The collaboration with Iconovo AB has shown that RCD405 has favorable properties for being able to be used in a powder formulation as an inhaled drug. Respiratorius expects to soon complete an efficacy study (ex vivo) with respiratory tissue from rat, dog, and humans. This is followed by the regulatory toxicological inhalation studies, which in their entirety constitute the last step before the start of the clinical development program.

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-08-2021 08:32 CET.

Johan Drott

President Respiratorius AB

+46 709-22 41 40

johan.drott@respiratorius.com

Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.